Firefly Neuroscience Secures $12.4 Million Financing to Advance AI-Powered Brain Health Technology

Firefly Neuroscience Secures Significant Financing

Firefly Neuroscience, Inc. (NASDAQ: AIFF), an artificial intelligence company focused on improving brain health outcomes, has announced the closure of a financing deal worth up to $12.4 million 1

1

2

2

. This funding consists of $2.4 million in senior secured convertible notes and an equity line of credit (ELOC) for up to $10 million.

Strategic Use of Funds

The company plans to utilize the proceeds for several key purposes:

1. Growth initiatives
2. Commercialization of its FDA-510(k) cleared Brain Network Analytics (BNA™) technology
3. General working capital requirements

Greg Lipschitz, Executive Chairman of Firefly, emphasized that this financing will strengthen the company's balance sheet and provide financial flexibility to execute their growth strategy 1

1

.

Brain Network Analytics (BNA™) Technology

Firefly's core offering, the Brain Network Analytics technology, represents a significant advancement in the field of neuroscience:

• Developed using AI and machine learning
• Based on a proprietary database of over 17,000 patient EEGs
• Covers twelve neurological and mental disorders
• Aims to revolutionize diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD 1

  1

  2

  2

Commercialization Strategy

The additional working capital will enable Firefly to accelerate two strategic commercialization pathways:

1. Partnering with neuroscience pharmaceutical companies
2. Supporting US neurologists and psychiatrists in diagnosis and patient care optimization

These efforts are aimed at improving outcomes for individuals suffering from brain health illnesses 1

1

2

2

.

Company Background and Technology Development

Firefly Neuroscience has spent the past 15 years building a comprehensive database of brain wave tests. This effort has resulted in:

• Securing patent protection
• Achieving FDA clearance for their technology
• Creating a standardized, high-definition longitudinal EEG database 1

  1

  2

  2

The BNA™ technology, when used in conjunction with an FDA-cleared EEG system, provides clinicians with comprehensive insights into brain function. This can enhance a clinician's ability to accurately diagnose mental and cognitive disorders and evaluate optimal therapies or drugs for patient outcomes 1

1

2

2

.

Market Position and Future Outlook

As Firefly launches BNA™ commercially, they are targeting two primary markets:

1. Pharmaceutical companies engaged in drug research and clinical trials
2. Medical practitioners for clinical use 1

   1

   2

   2

While the company expresses optimism about its future, it also acknowledges potential risks and uncertainties. These include challenges related to technology development, commercialization, market competition, and regulatory environments 1

1

2

2

.

This financing deal marks a significant milestone for Firefly Neuroscience as it seeks to establish itself as a leader in AI-powered brain health solutions. The success of their BNA™ technology could potentially transform the landscape of neurological and mental health diagnostics and treatment.